pipette
ENEnglish

Sample Size and Power Calculations Based on Endpoint Responsiveness: Applications to Trials of Disease-Modifying Therapies in Parkinson's Disease

M. Pedrera Gomez, C. Bernasconi, C. Mazza, S. Belachew

PreprintUso en el mundo real

En palabras de los autores

In Parkinson's disease (PD), early phase clinical trials of disease-modifying agents generally use the MDS-UPDRS Part III as the primary outcome measure of motor function, which typically requires a large sample and/or a long (12-18 months) treatment duration, even if a substantial treatment effect is assumed. This is due to the rather slow rate of early PD progression relative to the variability of the MDS-UPDRS Part III assessments. Using placebo-arm data from four recent large Phase 2 trials of early-stage PD (SPARK, PASADENA, PADOVA and LUMA), the sample size needed to detect a range of assumed treatment effects on MDS-UPDRS Part III progression was estimated. The trial sample size estimates obtained for MDS-UPDRS Part III and for smartphone-based sensor-derived motor functional composite (MFC) endpoints were compared using an approach based on relative responsiveness to disease progression. The calculations were also implemented in an interactive, publicly accessible application. Powering a one-year trial using the MFC1 endpoint, derived from three active assessments (6-minute walk, U-turn and Hand Pronation-Supination), or the MFC2, which adds 60-Second Typing, was projected to reduce the required sample size by more than half relative to the MDS-UPDRS Part III, assuming equivalent proportional treatment effects.

Resultado principalEl resumen no menciona limitaciones.

Apareció: martes, 6 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.09.29.26363876